Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Fred Y. Aoki"'
Autor:
Mark Loeb, Lorraine Moss, Pardeep Singh, Cassandra Howse, Lorne A. Babiuk, Mark Voight, Gregory Horsman, Tae H. Kim, Kevin Fonseca, Richard J. Webby, Paul Van Caeseele, Khami Chokani, Fred Y. Aoki, David J. D. Earn, Margaret L. Russell
Publikováno v:
Influenza and Other Respiratory Viruses
Please cite this paper as: Kim et al. (2012) Characteristics of respiratory viral infections during influenza season in Canadian Hutterite Communities. Influenza and Other Respiratory Viruses DOI:10.1111/irv.12021. Objectives: To determined the patho
Autor:
Fred Y. Aoki, Joanne M. Langley, I S Gorfinkel, L White, B Lasko, Allison McGeer, Guy Boivin, Jonathan B. Angel, Kim A. Papp, D Shu, Brian J. Ward, Louis Fries, G Stiver, P Dzongowski, M Alexander
Publikováno v:
Vaccine. 29:1921-1928
A randomized placebo-controlled double-blind trial of a nasally administered inactivated trivalent influenza vaccine formulated with partially purified meningococcal outer membrane proteins (OMP-TIV) was conducted in 1349 healthy adults aged 18-64 ye
Publikováno v:
Clinical Infectious Diseases. 41:1097-1104
Background. Famciclovir, the oral prodrug of penciclovir, is effective for the treatment of recurrent genital herpes. This randomized, clinic-initiated, double-blind trial compared the therapeutic efficacy and safety of treatment with famciclovir at
Publikováno v:
Canadian Journal of Public Health. 94:59-63
Objectives: Although the increased risk of hospitalization and mortality during influenza seasons has been documented extensively, there is a relative paucity of research on the impact of influenza-related illnesses on other health care use indicator
Autor:
M. John Gill, Jack H. Mendelson, Robert L. Bader, Donald Rosenthal, Ih Chang, Stephen D. Shafran, Stephen L. Sacks, Fred Y. Aoki, Walter F. Schlech, D. Lorne Tyrrell
Publikováno v:
The Journal of Infectious Diseases. 176:78-83
A multicenter, patient-initiated, double-blind, placebo-controlled trial of 15% undecylenic acid cream was conducted with 573 patients with recurrent herpes labialis. Treatment was applied 5 or 6 times daily until crusting and then thrice daily until
Autor:
Gloria Sim, David Murray, Edith Stephenson, Gwen Leche, Ruby Laughren, Joyce Chicoine, Lindsay E. Nicolle, M. McIntyre, Sylvia Graham, Fred Y. Aoki
Publikováno v:
Infection Control and Hospital Epidemiology. 17:732-736
OBJECTIVE To compare patient outcomes when percutaneous feeding tubes were changed routinely each month or only when necessary (prn). DESIGN Prospective, randomized, nonblinded crossover study of 6 months of routine monthly changes compared with 6 mo
Publikováno v:
Therapeutic drug monitoring. 33(6)
Background An influenza neuraminidase inhibitor drug, oseltamivir (Os) may be prescribed to renal transplant patients to prevent and treat influenza A and B illness. A pharmacokinetic (PK) interaction between Os and immunosuppressive drugs might adve
Autor:
Gerrald Predy, Yan Li, David W. Scheifele, Ethan Rubinstein, Scott A. Halperin, Laura Sauve, Barbara Law, Chris Sikora, Fred Y. Aoki, Greg Hammond
Publikováno v:
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 183(13)
Background: Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, promp
Publikováno v:
Clinical Pharmacology and Therapeutics. 54:23-27
We studied the short-term effect of oral doses of quinine and quinidine on the renal clearance of amantadine in healthy young (age range, 27 to 39 years) and older (age range, 60 to 72 years) adults of both genders in a three-limbed randomized crosso
Autor:
Stephen K. Tyring, Myron J. Levin, Spotswood L. Spruance, Johan Bring, Borje Darpo, Johan Harmenberg, Christopher M. Hull, Fred Y. Aoki, Eva Arlander
Publikováno v:
Journal of the American Academy of Dermatology. 64(4)
Prior pilot studies support the use of antiviral medications with topical corticosteroids for herpes simplex labialis (HSL). ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL.T